Seattle Genetics, Inc. (Nasdaq: SGEN) reports that SGN-75 shows tolerability and antitumor activity in a phase I in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE